@article{fbdd55637575401aaf86f45ec9c7d2e9,
title = "Targetable fusions of the FRK tyrosine kinase in ALKnegative anaplastic large cell lymphoma",
author = "G. Hu and S. Dasari and Asmann, {Y. W.} and Greipp, {P. T.} and Knudson, {R. A.} and Benson, {H. K.} and Y. Li and Eckloff, {B. W.} and J. Jen and Link, {B. K.} and L. Jiang and Sidhu, {J. S.} and Wellik, {L. E.} and Witzig, {T. E.} and Bennani, {N. N.} and Cerhan, {J. R.} and Boddicker, {R. L.} and Feldman, {A. L.}",
note = "Funding Information: This study was supported by research funding from Amgen Inc. Geoff Smith of Amgen Inc. and Jonathan Latham, a medical writer supported by funding from Amgen Inc., provided editorial assistance to the authors during the preparation of this manuscript. Funding Information: This study was supported by Award Numbers R01 CA177734 (to ALF), P30 CA15083 (Mayo Clinic Cancer Center) and P50 CA97274 (University of Iowa/Mayo Clinic Lymphoma SPORE) from the National Cancer Institute; CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS); Award Number CI-48-09 from the Damon Runyon Cancer Research Foundation (to ALF); Department of Laboratory Medicine and Pathology and Center for Individualized Medicine, Mayo Clinic; and the Predolin Foundation.",
year = "2018",
month = feb,
day = "1",
doi = "10.1038/leu.2017.309",
language = "English (US)",
volume = "32",
pages = "565--569",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",
}